The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Study ID
- NCT04398459
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Refractory/Relapsed Autoimmune Hemolytic Anemia
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ibrutinib — DRUGEach recruited subject will accept Ibrutinib treatment.
Study Details
This is an open-label, single-arm study to evaluate the safety and efficacy of Ibrutinib in subjects with refractory/relapsed autoimmune hemolytic anemia.
Key Dates
- Start date
- May 1, 2020
- Status verified
- Sep 2024
- Primary completion
- Dec 31, 2024
- Completion
- Jun 30, 2025
Study Design
- Enrollment
- 18 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: iBRIAN
Primary Outcome Measure
Overall response rate [ Time Frame: within 12 weeks ]